With the analysis among 3,944 patents, we discovered top 463 key players by total patent application. Bristol Myers Squibb Co., Genentech, Inc., F. Hoffmann-La Roche Ltd. are dominant in this area. They take 13.24% of the total patent filing.
New York, United States
Patent: 229
California, United States
Patent: 161
F. Hoffmann-La Roche Ltd.
Hessen, Germany
Patent: 93
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Sheng, China
Patent: 80
New York, United States
Patent: 72
Shanghai Hengrui Pharmaceutical Co., Ltd.
Shanghai Shi, China
Patent: 69
Shenzhou Cell Engineering Co Ltd.
Beijing Shi, China
Patent: 53
Five Prime Therapeutics, Inc.
California, United States
Patent: 50
Basel-Stadt, Switzerland
Patent: 49
With the analysis among 251 patents, we discovered top 55 start-ups by total patent application. DRAGONFLY Therapeutics, Inc., OriCell Therapeutics Co.,Ltd., Jiangsu Quanxin Biomedical Co Ltd are active in this area.
DRAGONFLY Therapeutics, Inc.
Massachusetts, United States
Patent: 21
OriCell Therapeutics Co.,Ltd.
Jiangsu Quanxin Biomedical Co Ltd
Jiangsu Sheng, China
Patent: 15
Cytoimmune Therapeutics, Inc.
California, United States
Patent: 12
Eucure (Beijing) Biopharma Co., Ltd.
Beijing Shi, China
Patent: 11
Washington, United States
Patent: 11
Institut National de la Santé et de la Recherche Médicale
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Shanghai Shi, China
Patent: 9
Modalis Therapeutics Corp.
With the analysis among related 3,331 patents applied in the last 5 years. We discover 500 most active companies in this area. The fast-growing Bristol Myers Squibb Co., Genentech, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd. take 8.56% of patent filing during this period.
New York, United States
Patent: 133
California, United States
Patent: 78
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Sheng, China
Patent: 74
F. Hoffmann-La Roche Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd.
Shanghai Shi, China
Patent: 63
Hessen, Germany
Patent: 54
New York, United States
Patent: 54
Shenzhou Cell Engineering Co Ltd.
Beijing Shi, China
Patent: 53
Fujian Sheng, China
Patent: 42
Delaware, United States
Patent: 41
With the analysis among related 3,331 patents in last 5 years, we discover 353 new entrants. Shenzhou Cell Engineering Co Ltd., Genmab A/S, BioNTech SE are the most active new entrants in this area.
Shenzhou Cell Engineering Co Ltd.
Beijing Shi, China
Patent: 53
Hovedstaden, Denmark
Patent: 36
Rheinland-Pfalz, Germany
Patent: 31
Shanghai Cp Guojian Pharmaceutical Co Ltd.
Shanghai Shi, China
Patent: 26
Gyeonggi-do, South Korea
Patent: 26
Mabwell (Shanghai) Bioscience Co., Ltd.
Shanghai Shi, China
Patent: 22
DRAGONFLY Therapeutics, Inc.
Massachusetts, United States
Patent: 21
Pumis Biotechnology (Zhuhai) Co., Ltd.
Guangdong Sheng, China
Patent: 20
Nanjing Shunxin Pharmaceutical Co., Ltd.
Jiangsu Sheng, China
Patent: 19
OriCell Therapeutics Co.,Ltd.
With the analysis among 710 patents, we discovered top 140 universities and scientific research institutions by total patent application. Xiamen University, President & Fellows of Harvard College, Hokkaido University are dominant in this area. They take 18.45% of the total patent filing.
Fujian Sheng, China
Patent: 52
President & Fellows of Harvard College
Massachusetts, United States
Patent: 26
Hokkaido, Japan
Patent: 24
China Pharmaceutical University
Jiangsu Sheng, China
Patent: 17
Institute of Basic Medical Sciences
Beijing Shi, China
Patent: 17
Henan Sheng, China
Patent: 17
The Johns Hopkins University
New Hampshire, United States
Patent: 9
Zhejiang Sheng, China
Patent: 9
Henan Sheng, China
Patent: 7